Trade agreements are usually discussed in boardrooms, export statistics and policy briefings, far removed from the lived reality of patients waiting outside oncology wards or families struggling to arrange money for a single vial of medicine. Yet India’s long-awaited free trade agreement with the European Union has entered this intimate space. By proposing the removal of customs duties of up to 11 percent on most pharmaceutical products, the deal carries the promise of cheaper imported medicines, smoother supply chains and improved access to some of the world’s most advanced therapies. The real question, however, is whether this promise will translate into meaningful relief for Indian patients or remain a theoretical advantage locked inside trade documents.

India’s pharmaceutical market sits at a unique juncture. On one hand, the country is celebrated as the pharmacy of the developing world, supplying affordable generic medicines to millions across continents. On the other, India remains heavily dependent on imports for high-end therapies, biologics, specialised drugs and advanced medical devices, many of which are manufactured in Europe. For years, customs duties, logistics costs and regulatory hurdles have added layers of expense to these imports, pushing prices further out of reach for ordinary patients. The proposed elimination of tariffs worth nearly €4 billion on EU exports to India has therefore sparked cautious optimism within healthcare circles.

In theory, removing customs duties should lower the landed cost of imported medicines. This is especially relevant for expensive cancer drugs, immunotherapies, enzyme replacement therapies and newer weight-loss drugs that are often manufactured in European facilities with strict quality controls. A reduction of even a few percentage points at the import stage can make a noticeable difference when hospitals procure medicines in bulk. For government-run schemes, public hospitals and large tertiary care centres, lower procurement costs could allow more patients to be treated within existing budgets or enable the inclusion of newer therapies that were previously considered too expensive.

The Indian Pharmaceutical Alliance has described the agreement as an important milestone, highlighting the long-standing trust between India and the European Union in pharmaceutical trade. Indian companies already play a critical role in supplying quality-assured, affordable medicines to Europe, and easier trade conditions could deepen this relationship. From an industry standpoint, the removal of EU tariffs on pharmaceuticals opens doors for greater exports of Indian generics and biosimilars, strengthening India’s position as a global manufacturing hub while reinforcing intellectual property commitments under international frameworks such as the TRIPS Agreement and the Doha Declaration.

Yet healthcare access is rarely shaped by a single policy lever. Drug pricing in India is a complex web of regulations, patents, supply chains and market behaviour. While essential medicines fall under price control mechanisms, many lifesaving drugs, especially biologics and novel therapies, operate outside these safeguards. Even if import duties are reduced to zero, manufacturers can continue to price their products at a premium due to patent protection and data exclusivity. For patients, this means that a trade deal alone cannot dismantle the financial barriers imposed by intellectual property regimes.

The situation becomes even more nuanced when the medicine leaves the port and enters the healthcare system. Cold-chain storage, specialised transport, hospital margins, distributor commissions and pharmacy mark-ups significantly influence the final price paid by patients. This is particularly true for injectables, biologics and personalised therapies that require strict handling protocols. Without parallel efforts to improve supply-chain efficiency and transparency, tariff reductions risk being absorbed silently within the system rather than reflected at the pharmacy counter.

Weight-loss drugs have emerged as a high-visibility talking point in discussions around the trade agreement. With global demand rising sharply and several leading products originating in Europe, lower import costs could improve availability in India. However, these medicines largely cater to a niche segment and remain unaffordable for the majority of the population. Their impact is likely to be modest compared to the potential gains in oncology, cardiology, endocrinology and rare disease treatments, where access gaps are both severe and consequential.

One of the less discussed but strategically important aspects of the agreement is its impact on active pharmaceutical ingredients and specialised intermediates. India relies on the European Union for several high-value inputs used in complex formulations. Lower tariffs on these components could reduce manufacturing costs for Indian pharmaceutical companies, indirectly benefiting patients through more competitive pricing and stable supply chains. Over time, this could also strengthen India’s export capacity, enhancing its role in global healthcare resilience.

Medical devices represent another critical dimension of the deal. The proposed elimination of tariffs of up to 27.5 percent on around 90 percent of medical, optical and surgical devices could significantly reshape India’s MedTech landscape. Cheaper imports of high-quality diagnostic equipment, implants and surgical tools may improve clinical outcomes and expand access to advanced procedures. At the same time, domestic manufacturers have raised legitimate concerns about maintaining a level playing field. Industry voices have emphasised the need for regulatory alignment, safeguards against predatory imports and mechanisms to prevent India from becoming a dumping ground for products routed through third countries.

For India’s ambition to become a top-five global MedTech hub, collaboration rather than competition will be key. Technology transfer, joint manufacturing and mutual recognition of quality standards could allow domestic firms to climb the value chain while ensuring patient safety. A carefully structured agreement, anchored in transparency and common ISO standards, has the potential to stimulate innovation rather than stifle it.

The most meaningful benefits of the India–EU trade agreement may not be immediately visible. The reduction in tariffs is a foundational step, not a final solution. Its true value lies in how it interacts with domestic policies on pricing, procurement and healthcare delivery. For public health schemes that operate under tight budgets, even incremental savings can translate into broader coverage or earlier adoption of innovative therapies. For private hospitals, lower import costs could reduce financial pressure, though whether these savings reach patients depends largely on institutional practices.

Stable and diversified supply chains are essential for healthcare security, a lesson reinforced by global disruptions during the pandemic. By deepening trade ties with the European Union, India can reduce vulnerabilities associated with over-reliance on a limited set of suppliers. This resilience benefits patients indirectly by minimising shortages, delays and price volatility, especially for critical medicines.

Critics argue that free trade agreements often prioritise industry interests over patient welfare. This concern is not unfounded. Without strong domestic regulation, monitoring and accountability, the benefits of tariff reductions can remain concentrated among manufacturers and distributors. Policymakers therefore face the challenge of ensuring that trade liberalisation aligns with public-health goals. Transparent pricing practices, efficient procurement systems and rational mark-up controls will be essential to convert policy advantages into patient-level impact.

At the same time, it would be simplistic to dismiss the agreement as inconsequential. Healthcare access is shaped incrementally, through a series of policy decisions that collectively alter the ecosystem. The India–EU trade deal has the potential to lower structural costs, encourage innovation and improve availability of advanced therapies. Whether it becomes a turning point or a missed opportunity depends on how effectively its provisions are implemented and complemented by domestic reforms.

For a country where out-of-pocket expenditure remains high and lifesaving medicines often push families into debt, any policy that promises cost relief deserves close scrutiny. The removal of customs duties may not revolutionise drug pricing overnight, but it can create conditions for gradual improvement. Over time, as competition increases and supply chains become more efficient, patients could experience tangible benefits, particularly in specialised care settings.

Ultimately, the success of the India–EU free trade agreement should be measured not by trade volumes or tariff savings alone, but by its impact on health outcomes.

Does it allow a cancer patient to access a therapy sooner?

Does it enable a public hospital to treat more patients within the same budget?

Does it strengthen India’s ability to manufacture complex medicines domestically?

These are the questions that matter. As trade negotiations move from paper to practice, the healthcare community will be watching closely. The agreement has opened a door. Whether India walks through it in a way that prioritises patients over profits will determine if this landmark deal becomes a reform or a genuine shift in the economics of survival.